Read by QxMD icon Read

Journal of Thrombosis and Thrombolysis

Tomasz Nowakowski, Krzysztof Piotr Malinowski, Rafał Niżankowski, Teresa Iwaniec, Anetta Undas
INTRODUCTION: Hypolysible fibrin clots composed of tightly packed fibers characterize patients with peripheral artery disease (PAD) especially those with critical limb ischemia (CLI). Little is known about the impact of a prothrombotic clot phenotype on restenosis following endovascular revascularization in CLI. The goal of this study was to compare fibrin clot properties and their determinants in CLI patients with restenosis after endovascular treatment (ET) and those free of this complication...
February 14, 2019: Journal of Thrombosis and Thrombolysis
Saman Salim, Moncef Zarrouk, Johan Elf, Anders Gottsäter, Signy Sveinsdottir, Peter Svensson, Stefan Acosta
It is unknown whether the risk factor profile for mesenteric venous thrombosis (MVT) is different from systemic venous thromboembolism (VTE). The aim of the present population-based study was to compare acquired and inherited risk factors in MVT versus VTE. Identification of all MVT patients at Skåne University Hospital between 2000 and 2015 was performed in patient records and AuriculA (Swedish anticoagulation registry). VTE patients were retrieved from the Malmö Thrombophilia Study (MATS), including 1465 consecutive unselected VTE patients between 1998 and 2008...
February 12, 2019: Journal of Thrombosis and Thrombolysis
Axel Rosell, Staffan Lundström, Nigel Mackman, Håkan Wallén, Charlotte Thålin
The association between venous thromboembolism (VTE) and occult cancer is well established. However, the benefit of cancer screening in all VTE patients remains controversial. The Registro Informatizado Enfermedad TromboEmbólica (RIETE) score is a recently proposed risk score to identify VTE patients at high risk of occult cancer. We evaluated the performance of the RIETE score in a routine clinical setting comprising patients presenting with VTE between January 1 and December 31, 2014, at Danderyd University hospital...
February 9, 2019: Journal of Thrombosis and Thrombolysis
Lukasz Koltowski, Mariusz Tomaniak, Lisa Gross, Bartosz Rymuza, Michal Kowara, Radoslaw Parma, Anna Komosa, Mariusz Klopotowski, Claudius Jacobshagen, Tommaso Gori, Daniel Aradi, Kurt Huber, Martin Hadamitzky, Steffen Massberg, Maciej Lesiak, Krzysztof J Filipiak, Adam Witkowski, Grzegorz Opolski, Zenon Huczek, Dirk Sibbing
To investigate the safety and efficacy of an early platelet function testing (PFT)-guided de-escalation of dual antiplatelet treatment (DAPT) in acute coronary syndrome (ACS) patients undergoing percutaneous coronary intervention (PCI) with bioresorbable vascular scaffolds (BVS). Early DAPT de-escalation is a new non-inferior alternative to 12-months DAPT in patients with biomarker positive ACS treated with stent implantation. In this post-hoc analysis of the TROPICAL-ACS trial, which randomized 2610 ACS patients to a PFT-guided DAPT de-escalation (switch from prasugrel to clopidogrel) or to control group (uniform prasugrel), we compared clinical outcomes of patients (n = 151) who received a BVS during the index PCI...
February 9, 2019: Journal of Thrombosis and Thrombolysis
Julia C Lea, Catherine K Floroff, Amanda I Ingemi, Gary R Zeevi
The association between time in therapeutic range (TTR) and clinical outcomes in patients with left ventricular assist devices (LVADs) on chronic warfarin therapy is not well understood. This study assessed TTR using the Rosendaal Method prior to suspected or confirmed pump thrombosis or ischemic stroke. Each patient served as their own control. Characteristics and TTR in 1, 2, and 3 months prior to thrombus (thrombus period) were compared to a thrombus-free period during 6 months to 3 months prior to thrombus (control period)...
February 9, 2019: Journal of Thrombosis and Thrombolysis
Nikolaos Spinthakis, Ying Gue, Mohamed Farag, Guogang Ren, Manivannan Srinivasan, Anwar Baydoun, Diana A Gorog
Impaired endogenous fibrinolysis is an adverse prognostic biomarker in acute coronary syndrome (ACS). Abnormally dense in vitro fibrin thrombi have been demonstrated in ACS patients and related to hypofibrinolysis using cumbersome, laboratory-based methods. We aimed to assess endogenous fibrinolysis using a point-of-care technique and relate this to clot architecture. From patients with ST-segment elevation myocardial infarction (STEMI), venous blood was drawn immediately on arrival to assess thrombotic status...
February 9, 2019: Journal of Thrombosis and Thrombolysis
Phil Wells, W Frank Peacock, Gregory J Fermann, Craig I Coleman, Li Wang, Onur Baser, Jeff Schein, Concetta Crivera
INTRODUCTION: Various risk stratification methods exist for patients with pulmonary embolism (PE). We used the simplified Pulmonary Embolism Severity Index (sPESI) as a risk-stratification method to understand the Veterans Health Administration (VHA) PE population. MATERIALS AND METHODS: Adult patients with ≥ 1 inpatient PE diagnosis (index date = discharge date) from October 2011-June 2015 as well as continuous enrollment for ≥ 12 months pre- and 3 months post-index date were included...
February 7, 2019: Journal of Thrombosis and Thrombolysis
Petar Stankovic, Robert Georgiew, Cornelius Frommelt, Sabine Hammel, Jan Wittlinger, Stephan Hoch, Danilo Obradovic, Nikolaos Dagres, Thomas Wilhelm
Patients taking oral anticoagulants (OACs) currently represent one-third of all patients treated for epistaxis and an upward trend is expected. New direct oral anticoagulants (DOACs) have been on the market for approximately 10 years. DOACs are favoured over Vitamin K-Antagonists (VKAs) in the current guidelines. There are barely studies that investigate the impact of DOACs on patients with epistaxis. A retrospective study was performed analysing all patients who had stationary treatment for epistaxis from 01...
February 7, 2019: Journal of Thrombosis and Thrombolysis
Paul Billoir, Thomas Duflot, Marielle Fresel, Marie Hélène Chrétien, Virginie Barbay, Véronique Le Cam Duchez
Factor V Leiden (FVL) mutation is the most common genetic risk factor for venous thromboembolism. In families with a history of thrombosis, FVL can be present in 18%. Thrombin generation test is commonly used as an evaluation tool of thrombotic risk. The objective of this study was to evaluate the thrombogenic potential of FVL in asymptomatic carriers and in patients with personal or familial history of thrombosis. This was a retrospective single center study including 160 patients. Among them, 43 had personal history of thrombosis and 117 had familial history of thrombosis...
January 30, 2019: Journal of Thrombosis and Thrombolysis
Dylan L Steen
No abstract text is available yet for this article.
January 30, 2019: Journal of Thrombosis and Thrombolysis
Armando Tripodi, Massimo Primignani, Sara Badiali, Fausto de Ruberto, Paola Granelli, Giulia Tosetti, Marigrazia Clerici, Lidia Padovan, Veena Chantarangkul, Erica Scalambrino, Flora Peyvandi
Obesity is a risk factor for cardiovascular diseases. The latter being dependent (at least in part) on plasma procoagulant imbalance (i.e., hypercoagulability). Information on hypercoagulability associated with obesity is scanty and mainly based on global traditional coagulation tests or on the measurement of individual components of coagulation (i.e., pro- and anticoagulants). Plasma from 33 obese subjects was investigated soon before endoscopic balloon placement and after removal (6 months later) by thrombin-generation procedures that are thought to represent much better than any other in vitro test the coagulation process occurring in vivo...
January 30, 2019: Journal of Thrombosis and Thrombolysis
Antonio Girolami, Silvia Ferrari, Elisabetta Cosi, Bruno Girolami, Maria Luigia Randi
To investigate the occurrence of thrombotic events (myocardial infarction, deep vein thrombosis or ischemic stroke) in a group of 39 cases of severe FXII deficiency during a mean 22.5 years follow-up. All patients seen in Padua during the years 1968-2006 will the object of this investigation. FXII was less than or 1% of normal in all cases. Factor FXII activity in unaffected family members was 98% (range 90-140%). No patient or control had a thrombotic event in the past and none were on anticoagulant therapy...
January 29, 2019: Journal of Thrombosis and Thrombolysis
Chaobo Bai, Yaoming Xu, Da Zhou, Jiayue Ding, Qi Yang, Yuchuan Ding, Xunming Ji, Ran Meng
Internal jugular vein (IJV) stenosis and cerebral venous sinus (CVS) stenosis belong to cerebral venous outflow insufficiency. This study aimed to analyze the similarities and differences between IJV stenosis and CVS stenosis. Patients with either IJV stenosis or CVS stenosis confirmed by contrast-enhanced magnetic resonance venography between October 2017 and July 2018 were enrolled in this retrospective study. The similarities and differences between IJV stenosis and CVS stenosis on the aspects of clinical and imaging features were compared...
January 28, 2019: Journal of Thrombosis and Thrombolysis
T Y Tang, R Goh, K Damodharan, E C Choke, T T Chong, Y K Tan
No abstract text is available yet for this article.
January 28, 2019: Journal of Thrombosis and Thrombolysis
Bruria Hirsh Raccah, Amihai Rottenstreich, Netanel Zacks, Ilan Matok, Haim D Danenberg, Arthur Pollak, Yosef Kalish
Direct oral anticoagulants (DOACs) are commonly administered at a level that is lower than that recommended by dose reduction criteria. This raises concern regarding the adequacy of anticoagulation achieved. To evaluate the relationship between inappropriate dosing and DOAC levels. Medical records of atrial fibrillation patients who underwent DOAC level testing during 2013-2017 were reviewed. The primary outcomes were drug levels under and above the expected steady-state range, and in the lowest and highest quartiles...
January 28, 2019: Journal of Thrombosis and Thrombolysis
Joanna Żuk, Agnieszka Snarska-Drygalska, Krzysztof Piotr Malinowski, Elżbieta Papuga-Szela, Joanna Natorska, Anetta Undas
Associations of Raynaud's phenomenon (RP) with venous thromboembolism (VTE) are unclear. We investigated the occurrence of RP together with prothrombotic state markers and fibrin clot properties in VTE patients. In this prospective cohort study we enrolled 360 patients free of known autoimmune disease. D-dimer, von Willebrand factor (vWF), plasma clot permeability (Ks ), clot lysis time (CLT) along with fibrinolysis activators and inhibitors were determined at least 3 months since the VTE event. The presence/absence of RP was diagnosed at least 6 months before VTE...
January 25, 2019: Journal of Thrombosis and Thrombolysis
Joseph J Shatzel, Dylan Mart, Jeffrey Y Bien, Ashray Maniar, Sven Olson, Timothy K Liem, Thomas G DeLoughery
Peripherally-inserted central catheters (PICCs) are commonly used during hospitalization. Unfortunately, their use can be complicated by catheter-related thrombosis (CRT). Current guidelines recommend 3-6 months of anticoagulation for patients with CRT after catheter removal. This recommendation is based on extrapolation of data on lower extremity thrombosis, as data is lacking regarding the efficacy and safety of more specific management strategies. Many providers feel catheter removal alone is a reasonable treatment option, particularly for patients at risk for bleeding...
January 23, 2019: Journal of Thrombosis and Thrombolysis
Kevin P Bliden, Gabe Raviv, Udaya S Tantry, Rahul Chaudhary, John W Cochran, Eliano P Navarese, Tricia Brannan, Ankit Vyas, Paul A Gurbel
Early assessment of thrombogenicity and antithrombotic drug effects may be important for therapeutic decision making in patients presenting with acute stroke. In this prospective, single center, pilot study, a bedside thrombelastography assay (TEG6s) was used to measure thrombogenicity and antithrombotic drug response in serial patients presenting emergently with symptoms of acute stroke (n = 90). TEG6s measures were compared against diagnosis obtained by NIH Stroke Scale/Score and imaging. Acute ischemic stroke (AIS) was diagnosed in 30 patients, intracerebral hemorrhage (ICH) in 19, transient ischemic attack (TIA) in 10 and stroke mimic (SM) in 31...
January 23, 2019: Journal of Thrombosis and Thrombolysis
Yugo Yamashita, Takeshi Morimoto, Hidewo Amano, Toru Takase, Seiichi Hiramori, Kitae Kim, Maki Oi, Masaharu Akao, Yohei Kobayashi, Mamoru Toyofuku, Toshiaki Izumi, Tomohisa Tada, Po-Min Chen, Koichiro Murata, Yoshiaki Tsuyuki, Syunsuke Saga, Tomoki Sasa, Jiro Sakamoto, Minako Kinoshita, Kiyonori Togi, Hiroshi Mabuchi, Kensuke Takabayashi, Hiroki Shiomi, Takao Kato, Takeru Makiyama, Koh Ono, Takeshi Kimura
The influence of anemia on the long-term clinical outcomes has not been fully evaluated in patients with venous thromboembolism (VTE). We evaluated the influence of anemia among 3012 patients in the COMMAND VTE Registry with a median follow-up period of 1219 days. The outcomes measures were ISTH major bleeding, recurrent VTE and all-cause death. There were 1012 patients (34%) with moderate/severe anemia (Hb ≤ 10.9 g/dl), 615 patients (20%) with mild anemia (Hb 11.0-12.9 g/dl for men, and 11.0-11.9 g/dl for women), and 1385 patients (46%) without anemia...
January 23, 2019: Journal of Thrombosis and Thrombolysis
Koji Takaishi, Shokichi Tsukamoto, Chikako Ohwada, Masahiro Takeuchi, Yohei Kawasaki, Yurie Nagai, Tatsuzo Mishina, Miki Yamazaki, Yusuke Isshiki, Kensuke Kayamori, Kenji Kimura, Yutaro Hino, Nagisa Oshima-Hasegawa, Shio Mitsukawa, Yusuke Takeda, Naoya Mimura, Tohru Iseki, Chiaki Nakaseko, Emiko Sakaida
Anti-platelet agents or anticoagulants are administered for patients with multiple myeloma (MM) receiving immunomodulatory drugs (IMiDs) to prevent thrombotic events (TEs). However, there is a discrepancy between current guidelines and clinical practice in thromboprophylaxis and the varied incidence of TEs depending on patient cohort. Therefore, a consensus on the optimal thromboprophylactic strategy is needed. To determine an appropriate strategy for the prevention of TEs in MM patients receiving IMiDs, we performed a retrospective single-institution analysis...
January 23, 2019: Journal of Thrombosis and Thrombolysis
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"